Brain Tumor Pathology

, Volume 28, Issue 4, pp 317–327

A case of anaplastic clear-cell ependymoma presenting with high erythropoietin concentration and 1p/19q deletions

  • Kenichiro Asano
  • Kanae Kudo
  • Fumiaki Mori
  • Hiroki Ohkuma
  • Koichi Wakabayashi
Case Report


We describe a 19-year-old woman with onset of epileptic seizure, and a small mural nodule and multicystic lesions with severe brain edema located in the right frontal lobe. At surgery, the tumor and a clear margin was removed, and symptoms improved postoperatively. Extended local radiotherapy (60 Gy) was performed. Histopathological examination revealed oligodendroglioma-like tumor cells with a perinuclear halo. The tumor cells extended processes toward CD34-positive proliferating vessels, which resemble a basement membrane. These proliferating vessels formed a tumor membrane so that there was a clear margin between the tumor and brain tissue. Tumor cells were positive for epithelial membrane antigen in a dot-like pattern. MIB-1 staining index was 50.6%. Electron microscopy showed cilia and zipper-like junctions, and anaplastic clear-cell ependymoma grade III was diagnosed. A characteristic of the case was formation of a tumor membrane by proliferating tumor blood vessels. Fluorescence in situ hybridization showed 1p/19q deletions, and the concentration of erythropoietin in the cyst fluid was abnormally high, at 1,859.4 mIU/ml. Erythropoietin and erythropoietin receptors were verified with immunohistochemical staining.


Anaplastic clear-cell ependymoma Erythropoietin 1p/19q deletions 


  1. 1.
    The Community of Brain Tumor Registry of Japan (2009) Report of Brain Tumor Registry of Japan (1984–2000), 12th end. Neurol Med Chir (Tokyo) 49 suppl:1–22Google Scholar
  2. 2.
    McLendon RE, Wiestler OD, Kros LM, Korshunov A, Ng HK (2007) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World health organization classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 74–78Google Scholar
  3. 3.
    Preusser M, Laggner U, Haberler C, Heinzl H, Budka H, Hainfellner JA (2006) Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology. Histopathology 48:438–444PubMedCrossRefGoogle Scholar
  4. 4.
    Fouladi M, Helton K, Dalton J et al (2003) Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 98:2232–2244PubMedCrossRefGoogle Scholar
  5. 5.
    Min KW, Scheithauer BW (1997) Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Am J Surg Pathol 21:820–826PubMedCrossRefGoogle Scholar
  6. 6.
    Kawano N, Yada K, Aihara M, Yagishita S (1983) Oligodendroglioma-like cells (clear cells) in ependymoma. Acta Neuropathol 62:141–144PubMedCrossRefGoogle Scholar
  7. 7.
    Kawano N, Yada K, Yagishita S (1989) Clear cell ependymoma: a histological variant with diagnostic implications. Virchows Arch A Pathol Anat Histopathol 415:467–472PubMedCrossRefGoogle Scholar
  8. 8.
    Kurimoto M, Nagai S, Hamada H et al (2009) Malignant transformation of supratentorial clear cell ependymoma. Neuropathology 29:299–302PubMedCrossRefGoogle Scholar
  9. 9.
    Kubota T, Hirano A, Tanaka R, Takahashi H (2006) Fine structural study of a cerebral tumor characterized by a honeycomb appearance after a 20-year post-mortem interval. Neuropathology 26:158–160PubMedCrossRefGoogle Scholar
  10. 10.
    Asano K, Takeda T, Nakano T, Ohkuma H (2010) Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol 27:1–6PubMedCrossRefGoogle Scholar
  11. 11.
    Cosar M, Hatiboglu MA, Iplikcioglu AC, Ozcan D (2006) Parasagittal leptomeningeal hemangioblastoma: case report. Neurol Med Chir (Tokyo) 46:294–297CrossRefGoogle Scholar
  12. 12.
    Karabagli H, Karabagli P, Alpman A, Durmaz B (2007) Congenital supratentorial cystic hemangioblastoma. Case report and review of the literature. J Neurosurg 107(6 Suppl):515–518PubMedGoogle Scholar
  13. 13.
    Takeuchi H, Hashimoto N, Kitai R, Kubota T (2008) A report of supratentorial leptomeningeal hemangioblastoma and a literature review. Neuropathology 28:98–102PubMedCrossRefGoogle Scholar
  14. 14.
    Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314–322PubMedGoogle Scholar
  15. 15.
    Kawano N, Utsuki S (2009) Ependymoma. In: Kawamoto K, Yoshida J, Nakazato Y (eds) Color atlas of brain tumor pathology, 3rd edn. Igakusyoin, Tokyo, pp 52–55Google Scholar
  16. 16.
    Blümcke I, Müller S, Buslei R, Riederer BM, Wiestler OD (2004) Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol 108:89–96PubMedCrossRefGoogle Scholar
  17. 17.
    Rodriguez FJ, Scheithauer BW, Robbins PD et al (2007) Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol 113:313–324PubMedCrossRefGoogle Scholar
  18. 18.
    Gessi Mr, Marani C, Geddes J, Arcella A, Cenacchi G, Giangaspero F (2005) Ependymoma with neuropil-like islands: a case report with diagnostic and histogenetic implications. Acta Neuropathol 109:231–234PubMedCrossRefGoogle Scholar
  19. 19.
    Hasselblatt M, Paulus W (2003) Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. Acta Neuropathol 106:385–388PubMedCrossRefGoogle Scholar
  20. 20.
    Kawano N, Yasui Y, Utsuki S, Oka H, Fujii K, Yamashina S (2004) Light microscopic demonstration of the microlumen of ependymoma: a study of the usefulness of antigen retrieval for epithelial membrane antigen (EMA) immunostaining. Brain Tumor Pathol 21:17–21PubMedCrossRefGoogle Scholar
  21. 21.
    Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S (2008) Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med 10:41PubMedGoogle Scholar
  22. 22.
    Mannoji H, Becker LE (1988) Ependymal and choroid plexus tumors. Cytokeratin and GFAP expression. Cancer 61:1377–1385PubMedCrossRefGoogle Scholar
  23. 23.
    Sharma MC, Ghara N, Jain D, Sarkar C, Singh M, Mehta VS (2009) A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology 29:148–155PubMedCrossRefGoogle Scholar
  24. 24.
    Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR (2010) Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 12:862–870PubMedCrossRefGoogle Scholar
  25. 25.
    Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD (1996) Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 40:376–380PubMedCrossRefGoogle Scholar
  26. 26.
    Grasso G, Sfacteria A, Passalacqua M et al (2005) Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. Neurosurgery 56:821–827PubMedCrossRefGoogle Scholar
  27. 27.
    Sakanaka M, Wen TC, Matsuda S et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635–4640PubMedCrossRefGoogle Scholar
  28. 28.
    Mohyeldin A, Dalgard CL, Lu H et al (2007) Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg 106:338–350PubMedCrossRefGoogle Scholar
  29. 29.
    Yin D, Kawabata H, Tcherniamtchouk O, Huynh T, Black KL, Koeffler HP (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31:1193–1198PubMedGoogle Scholar
  30. 30.
    Batra S, Perelman N, Luck LR, Shimada H, Malik P (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487PubMedCrossRefGoogle Scholar
  31. 31.
    Hassouna I, Sperling S, Kim E et al (2008) Erythropoietin augments survival of glioma cells after radiation and temozolomide. Int J Radiat Oncol Biol Phys 72:927–934Google Scholar
  32. 32.
    Korshunov A, Neben K, Wrobel G et al (2003) Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 163:1721–1727PubMedCrossRefGoogle Scholar
  33. 33.
    Rousseau E, Palm T, Scaravilli F et al (2007) Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer 6:47PubMedCrossRefGoogle Scholar
  34. 34.
    Rickert CH, Korshunov A, Paulus W (2006) Chromosomal imbalances in clear cell ependymomas. Mod Pathol 19:958–962PubMedCrossRefGoogle Scholar
  35. 35.
    Chamberlain MC, Johnston SK (2009) Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 115:4775–4782PubMedCrossRefGoogle Scholar
  36. 36.
    Green RM, Cloughesy TF, Stupp R et al (2009) Bevacizumab for recurrent ependymoma. Neurology 73:1677–1680PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2011

Authors and Affiliations

  • Kenichiro Asano
    • 1
  • Kanae Kudo
    • 1
  • Fumiaki Mori
    • 2
  • Hiroki Ohkuma
    • 1
  • Koichi Wakabayashi
    • 2
  1. 1.Department of NeurosurgeryHirosaki University Graduate School of MedicineHirosakiJapan
  2. 2.Department of Neuropathology, Institute of Brain ScienceHirosaki University Graduate School of MedicineHirosakiJapan

Personalised recommendations